No molecule has captured the longevity supplement market’s imagination quite like NAD+ — nicotinamide adenine dinucleotide. The reasons are scientifically legitimate: NAD+ is a central cofactor in cellular energy metabolism and a substrate for sirtuins (the enzyme family central to David Sinclair’s longevity research at Harvard), PARP enzymes involved in DNA repair, and CD38, an NAD-consuming enzyme that increases with age and inflammation. NAD+ levels decline measurably with age — roughly 50% by midlife in some tissue measurements — and this decline is causally implicated in several hallmarks of aging in animal models.
The commercial result has been a proliferation of NAD+ precursor supplements and intravenous NAD+ infusion services, coexisting in a market where price points vary by 10x and where pharmacokinetic distinctions that matter enormously to clinical outcomes are rarely communicated to consumers. Making an informed decision requires understanding the biochemistry that precursor companies often simplify and that IV clinics rarely explain completely.
The Biochemistry: Why NAD+ Cannot Simply Be Supplemented Directly
NAD+ itself is a large, charged molecule that does not pass through cell membranes efficiently and has essentially zero oral bioavailability when taken as a supplement. The body synthesizes NAD+ from precursors via two primary pathways: the Preiss-Handler pathway (from niacin/nicotinic acid) and the salvage pathway (from nicotinamide, NMN, and NR). Oral NAD+ supplements are therefore functionally useless for raising intracellular NAD+ — a fact that is not always prominently disclosed on product labels.
The precursors, however, are genuinely effective through different mechanisms. Niacinamide (nicotinamide, the amide form of vitamin B3) is the most abundant endogenous NAD+ precursor and enters the salvage pathway directly. It is inexpensive, well-studied, and has demonstrated measurable NAD+ elevation in clinical trials at doses of 250-500mg daily. The critical caveat is that niacinamide at high doses also inhibits sirtuin activity — the very enzymes whose activation is a primary theoretical goal of NAD+ supplementation. This dose-dependent paradox makes niacinamide a complicated choice for longevity-focused supplementation, though it remains entirely appropriate for nicotinamide replacement therapy in clinical contexts.
Nicotinamide riboside (NR), sold commercially as Tru Niagen by ChromaDex and under the Elysium Health brand as Basis (in combination with pterostilbene), is a downstream precursor that converts to NMN and then to NAD+ via the salvage pathway. Clinical trials have established that NR at 300-1000mg daily consistently elevates whole-blood NAD+ levels by 40-90% compared to baseline, with good tolerability. A key 2020 paper by Martens and colleagues published in Nature Communications demonstrated significant NAD+ increases with NR in healthy middle-aged and older adults, along with beneficial changes in metabolic flexibility in a subset of participants.
Nicotinamide mononucleotide (NMN) is one step closer to NAD+ in the biosynthetic pathway. David Sinclair has publicly disclosed taking 1,000mg of NMN daily along with resveratrol, and his lab’s mouse research with NMN has produced remarkable results — including a Cell Metabolism 2013 paper demonstrating that NMN supplementation in aging mice improved energy metabolism, physical activity, and multiple metabolic parameters. Human trials are now accumulating. A 2022 randomized controlled trial in Nature Aging (Igarashi et al.) showed that 250mg NMN daily for 12 weeks significantly elevated blood NAD+ metabolites and improved muscle function in older men. The commercial market for NMN has exploded accordingly, though price variance ($30-$300 per month at similar dosages) reflects significant quality variation.
Where IV NAD+ Fits
Intravenous NAD+ administration bypasses oral bioavailability constraints entirely. When NAD+ is infused directly into the bloodstream at doses of 500mg to 1,000mg (the typical clinical range), it produces a large spike in circulating NAD+ that drives uptake into tissues via specific transport mechanisms. This is the central pharmacokinetic argument for IV over oral: regardless of how efficient an oral precursor’s conversion pathway is, IV administration of NAD+ itself creates plasma concentrations that simply cannot be replicated orally.
The practical outcomes reported by patients and IV clinics include acute improvements in mental clarity, physical energy, and reduction of withdrawal symptoms in addiction contexts — this last use case having the oldest clinical history. The Entero Medics approach to addiction treatment using IV NAD+ (pioneered in South Africa and now offered through facilities including Springfield Wellness Center in Louisiana) predates the longevity application and involves higher doses (500-1,500mg per day over 10 days) than typical longevity infusions.
For longevity purposes, a typical protocol involves 500mg IV NAD+ once weekly or every two weeks, requiring a 2-4 hour infusion session at rates slow enough to avoid the facial flushing, chest tightness, and nausea that many patients experience at rapid infusion rates. Pricing ranges from $300 to $800 per session at premium concierge and longevity clinics. Next Health in Los Angeles offers IV NAD+ at $399 per 500mg infusion; Drip IV in New York runs approximately $350 for a similar dose.
The Honest Pharmacokinetic Comparison
The IV vs. oral debate hinges on a question that has not been fully resolved in published human research: does the acute, high-amplitude NAD+ spike produced by IV infusion translate into better long-term biological outcomes than the sustained, moderate elevation produced by daily oral precursors?
There are reasons to believe the answer may favor oral supplementation for most longevity purposes. First, NAD+ has a short half-life in plasma (approximately 2-3 hours), meaning the IV-produced spike normalizes relatively quickly. Second, the cellular machinery that utilizes NAD+ — sirtuins, PARPs, CD38 — may respond more favorably to sustained adequate availability than to periodic dramatic spikes followed by return to baseline. Third, the cost-to-sustained-elevation ratio strongly favors oral precursors: $100/month of quality NMN maintains a 50-80% elevation in NAD+ metabolites continuously, whereas $400/week of IV produces a larger but transient spike.
The cases where IV NAD+ offers clearer advantages are: acute neurological support (addiction recovery, post-surgery neurological recovery, post-COVID fatigue) where immediate, large-magnitude NAD+ elevation may have distinct value; individuals with malabsorption disorders that impair oral precursor bioavailability; and clinical contexts where rapid repletion of severely depleted NAD+ is medically indicated.
Practical Guidance
For most healthy individuals pursuing NAD+ optimization as a longevity strategy, the evidence-based approach begins with oral supplementation. NMN at 500-1000mg daily or NR at 500mg daily from a quality-verified supplier (third-party tested, COA available) represents the most cost-effective starting point. Elysium Health’s Basis formulation has published clinical data; Tru Niagen (NR) by ChromaDex has the most substantial peer-reviewed backing of any single commercial supplement in this category.
For individuals who have established a baseline with oral precursors and wish to assess whether IV produces a subjectively or objectively discernible additional benefit, a trial of 4-6 weekly IV NAD+ sessions at 500mg while maintaining wearable data tracking (HRV, sleep quality, energy via WHOOP or Oura) provides a structured personal comparison. This approach costs $1,600-$3,200 as a trial but generates personal data that informs whether continued investment is warranted for the individual.
What neither approach fully addresses is the fundamental uncertainty about long-term human NAD+ supplementation outcomes. The mouse data is extraordinary; the human trial durations to date (typically 4-16 weeks) are insufficient to establish effects on aging trajectories. This is where scientific honesty and commercial marketing most dramatically diverge — and where calibrated optimism, rather than certainty, remains the appropriate posture.
[ QUICK POLL // 60 SECONDS ]